City of San Antonio enacting plan to better leverage military medical assets

  The San Antonio Military Life Science Commercialization Action Plan seeks to better leverage ...

Local PTSD Research Leader Receives Top Award for Innovation in Bioscience

  Posted by Jim Forsyth, News Radio 1200 WOAI Dr. Alan Peterson of U.T. Health, who has in ...


Learn to Prepare IND for Small Molecule Drugs

How does a drug development program evolve from a brilliant research idea? Join Southwest Research Institute ...
San Antonio biotech acquires U.K. wound-care company
June 8, 2018

Acelity LP President and CEO Andrew Eckert says the company's acquisition of England's Crawford Healthcare is a game-changer for the San Antonio-based biotech. CARLOS JAVIER SANCHEZ | SABJ

By W. Scott Bailey –Senior Reporter, San Antonio Business Journal

Acelity LP, already considered one of the world’s largest wound-care companies, is getting considerably bigger. The San Antonio-based biotech has acquired Crawford Healthcare, a fast-growing wound-care and dermatology business, which has its headquarters near Manchester, England.

Acelity officials would not disclose terms of the deal. But the company did confirm it has secured all of its Crawford’s assets.

This transaction is expected to create what Acelity has characterized as the “world’s most expansive wound-care portfolio,” giving it far more breadth and depth in a $4 billion market. In addition to securing Crawford’s commercial products, Acelity is also gaining access to the British biotech’s research and development capabilities, as well as its manufacturing operations in Cheshire, England.

Crawford has made its mark internationally with the development and commercialization of innovative treatments for the care and repair of skin. Acelity officials said Crawford’s wound-dressing lines complement the San Antonio company’s portfolio.

“Crawford’s talented team, highly complementary line of advanced wound-dressings and track record of patient-focused innovation make them a terrific partner to accelerate our global growth,” Acelity President and CEO Andrew Eckert said in a statement. “This transaction solidifies our ability to offer the most comprehensive line of wound-care solutions and will enable us to create and consolidate leading positions in high-growth market segments ... and enhance our innovation expertise for the benefit of clinicians and patients around the world.”

Richard Anderson, CEO of Crawford Healthcare, said the company’s rapid growth has come from a “focused investment” in innovative products. He added that, by becoming part of the “world’s largest wound-care company” will provide the entity the scale needed to pursue its commercial potential in the U.S. and to expand opportunities in additional international markets.

Anderson will continue to lead Crawford as part of the deal with Acelity. The two companies will work over the remainder of the year to put in place an integration plan.

Stay informed. Subscribe to BioMed SA news alerts.